Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PF-00610355 450 µg | Experimental | An orally inhaled dose of PF-00610355 450 µg |
|
| PF-00610355 1200 µg | Experimental | An orally inhaled dose of PF-00610355 1200 µg |
|
| moxifloxacin 400 mg | Active Comparator | A single oral dose of moxifloxacin 400 mg on Day 4. |
|
| placebo | Placebo Comparator | A single oral dose of non-matched placebo on Day 4. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-00610355 | Drug | An orally inhaled dose of PF-00610355 450 µg on days 1 to 4 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| To assess whether multiple dose administration of PF00610335 has the potential to affect QTc in healthy volunteers | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the effects of a positive control (moxifloxacin) on QTc interval in healthy volunteers | 24 hours | |
| To asses the the relationship between plasma concentrations of PF00610335 and its effects, if any on the QTc interval | 24 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Brussels | 1070 | Belgium |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| ID | Term |
|---|---|
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C552705 | N-((4'-hydroxybiphenyl-3-yl)methyl)-2-(3-(2-((-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)phenyl)acetamide |
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PF-00610355 |
| Drug |
An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4 |
|
| moxifloxacin | Drug | A single oral dose of moxifloxacin 400 mg on Day 4. |
|
| placebo | Drug | A single oral dose of non-matched placebo on Day 4. |
|
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |